

Πανεπιστήμιο Θεσσαλίας

Τμήμα Ιατρικής

Πρόγραμμα Μεταπτυχιακών Σπουδών

Μεθοδολογία Βιοϊατρικής Έρευνας, Βιοστατιστική και Κλινική Βιοπληροφορική

Καθηγητής: Η. Ζιντζαράς

Μεταπτυχιακή εργασία με τίτλο:

«Assess the reporting quality of randomized-controlled trials in multiple sclerosis from 2000 to 2015, based on CONSORT statement»



Φοιτητής: Ρίκος Δημήτριος

Supervisor: Γ.Μ. Χατζηγεωργίου

Evaluator 1: Η. Ζιντζαράς

Evaluator 2: Ι. Στεφανίδης

Αύγουστος 2015

Assess the reporting quality of randomized-controlled trials in multiple sclerosis from 2000 to 2015, based on CONSORT statement

Rikos D.^{1,2}

PURPOSE: Randomized controlled trials (RCTs) are the best tool to evaluate the effectiveness of clinical interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement is an evidence based approach to improve the quality of reporting of RCTs. The aim of this study was to evaluate the reporting quality of published RCTs concerning multiple sclerosis from 2000 to 2015 according to a checklist based on the CONSORT statement.

METHODS: PubMed was searched for English-language RCTs involving patients with multiple sclerosis (MS). Trials were considered eligible when participants were randomly assigned to at least two medicinal treatment arms and included patients with MS. Quality of reporting was assessed using a 39-item questionnaire based on the CONSORT checklist. Articles were grouped in three 5-year periods and comparisons were made using descriptive statistics.

RESULTS: The search identified 75 eligible articles for analysis. 20 of the 38 items of the checklist were addressed in 75% or more of the studies. Reporting of more than 75% of CONSORT items was increased during the three equal time periods from 2000 to 2015 ($p < 0.05$).

CONCLUSIONS: Quality of reporting in RCTs focusing on multiple sclerosis is showing improvement over time but remains unsatisfactory. Further improvement of reporting is necessary to assess the validity of clinical research

1. University General Hospital of Larissa. Neurology Department. Resident
2. Hellenic Air Force, 110 Combat Wing, Captain MD, FS, DAvMed

Abbreviations and Acronyms

RCT = randomized controlled trial

CONSORT = Consolidated Standards of Reporting Trials

ITT = intention-to-treat

MS = Multiple Sclerosis

RRMS = Relapsing Remitting MS

SPMS = Secondary Progressive MS

PPMS = Primary Progressive MS

CIS = Clinically Isolated Syndrome

INTRODUCTION

The publication of scientific research results and reporting of biomedical information are linked with the development of clinical therapeutic trials. The highest rank within the clinical studies is occupied by the randomized controlled trials (RCT) which consider to be “the most powerful tool in modern clinical research”(1). RCTs represent a key research activity with the potential to improve the quality of health care and control costs through careful comparison of alternative treatments or placebo (2). This happens mainly because the act of randomizing patients to receive or not receive the intervention ensures that, on average, all other possible causes are equal between the two groups. Thus, any significant differences between groups in the outcome event can be attributed to the intervention and not to some other unidentified factor (3). However, the overwhelming amount of information available in biomedical journals during the past 50 years has created problems in a variety of areas, such as publication or selection bias (4, 5). Readers need to know the quality of the trials, in order to assess the strengths and limitations of RCTs (6, 7). In addition, healthcare providers depend upon the reporting of methodological factors in the reports of RCTs to allow them to determine the validity of the trials upon which they base their clinical practice and their treatment guidelines (8, 9).

It is clear that the evaluation of the quality of randomized controlled trials (RCTs) is central to evidence-based health care. Important methodologic detail may, however, be omitted from published reports, and the quality of reporting is therefore often used as a proxy measure for quality (10). A well conducted but badly reported trial will be misclassified and a general, unclear and inaccurate reporting may reflect faulty methods (7, 11, 12). Additionally since pharmaceutical industry is the major funder of trials, information on funding sources and the role of the industry is also essential.

An overwhelming body of evidence stating that the completeness of reporting of randomized controlled trials (RCTs) is not optimal has accrued over time. In the mid-1990s, in response to these concerns, an international group of clinical trialists, statisticians, epidemiologists, and biomedical journal editors developed the CONSolidated Standards Of Reporting

Trials (CONSORT) Statement. The CONSORT Statement, most recently updated in March 2010, is an evidence-based minimum set of recommendations including a checklist and flow diagram for reporting RCTs and is intended to facilitate the complete and transparent reporting of trials and aid their critical appraisal and interpretation (13). CONSORT urges completeness, clarity, and transparency of reporting, which simply reflects the actual trial design and conduct (14). However, the CONSORT statement should not be used as a quality appraisal tool but rather as a guide for reporting of RCTs.

A number of publications have studied the quality of reports of RCTs in subspecialties of medicine (15-20). In 2012 a review of the quality of reports in multiple sclerosis was also published including 53 articles from five leading medical journals from 1993 to 2010 (21).

Multiple sclerosis is one of the most common autoimmune disorders affecting the CNS (22) with yet unsatisfactory explanation of pathophysiology and inadequate treatment making good quality trials a necessity.

In this study we analyzed the quality of reporting of Randomized Controlled Trials involving patients with Multiple Sclerosis (Relapsing Remitting MS, Primary Progressive MS, Secondary Progressive MS, Clinically Isolated Syndrome and first demyelinating event suggestive of MS) using the items of the revised CONSORT 2010 statement checklist (14) with an additional item.

METHODS

Data Sources and Search Strategies

We searched PubMed (1st of January 2000 to 15th of July 2015) for reports on RCTs involving patients with MS. As a search criterion the phrase “Multiple Sclerosis” was used. We used as filters the “Randomized Controlled Trial” type of article, “English” language and “Humans” for species.

Eligibility of Studies

Trials were eligible if they had randomly assigned participants to at least two medicinal treatment arms and included patients with MS including all different types of the disease (Relapsing Remitting MS, Primary Progressive MS, Secondary Progressive MS, Clinically Isolated Syndrome and first demyelinating event suggestive of MS). Reports of trials on MS symptoms treatments, non-medicinal treatments, dose comparison studies, small pilot studies and any article with information resulting from a previous conducted trial (post-hoc analysis, sub-group analysis, sub-studies) were excluded.

Reporting Assessment Tool

As assessment tool for reporting quality we used the revised CONSORT 2010 checklist (<http://www.consort-statement.org>) which is a 25-item checklist with sub-items (total 37 items) in which we added an additional item (No 13) when an article included or not a participant flow diagram. There was no training of the reviewer on the CONSORT use. As guidelines the CONSORT explanation and elaboration document (available at the CONSORT web page) was used. From the total of 75 eligible trials 40 were conducted before 2010 when the revised CONSORT version was published and 35 after 2010. We used the revised version for all of the articles. The full CONSORT checklist can be found at the Appendix.


Evaluation - Analysis

Evaluation was made using the Microsoft Excel 2010 software. During the evaluation the following procedures were followed: a. all items were investigated in terms of whether they reported, not actually carried out during the trial b. when an item was reported in a different section of the trial (title, abstract, methods, results, discussion) it was considered as a negative response except of the information on “other information” section which was considered as positive regardless where it was mentioned c. alternative responses (apart of yes or no) or unclear responses to each question were coded as negative responses. We separated the articles in three five-year time periods. From 2000 to 2004. From 2005 to 2009 and from 2010 to 2015. We also separated the reporting items into five

groups. 1. Title/Abstract and Introduction 2. Methods 3. Results 4. Discussion 5. Other information.

We calculated the greater than 75% (>75%) compliance with the checklist, meaning the percentage of the articles (overall and by time period) that reported at least 75% of the 38 checklist items. We also calculated the percentage of the items that was reported in at least 75% of the articles in overall and by item group (title and abstract, methods, results, discussion, other) for the 15 year period and by 5-year period. Comparison between >75% compliance among different time periods was made using the chi-square statistic for a 2x3 table (SPSS v.21 software).

Web search, review, evaluation and statistics was made by the author.



RESULTS

Eligible studies

The process was made in four steps. PubMed search (<http://www.ncbi.nlm.nih.gov/pubmed>) using the criteria mentioned in methods, returned 1003 related articles which were reviewed by title. 628 were excluded because they were not relevant or had a non medicinal intervention (behavioral treatment, exercise, herbal) or were not randomized trials. The 385 articles left reviewed by abstract and 260 excluded for the same reasons. 125 articles searched for full text from which 36 were not found due to accessibility reasons. Finally 89 full text articles reviewed from which 14 excluded. 75 articles finally were evaluated including a total of 6150 randomized patients. A list with these 75 articles can be found at the Appendix.

Main Results

Of a total of 75 articles, 12 were published the period 2000-2004, 28 the period 2005-2009 and 35 the period 2010-2015. The percentages of articles reporting each item by publishing period is shown at Table 1. 20 checklist items (52.6%) were reported from 75% or more of the articles published from 2000 to 2015, 17 (44.7%) the period 2000 to 2004, 19 (50%) the period 2005 to 2009 and 24 (63.2) the period 2010 to 2015 showing a trend of increase in reporting CONSORT items after its revision. The numbers and percentages showing the checklist items that was reported by 75% or more of the articles by period and by group is shown at Table 2 and Figure 1. Most of the items showed an increase in reporting during time.




Figure 1 Percentage of items reported in >75% of the articles by period and by group

The >75% compliance with CONSORT by time period was: overall: 22 (29.33%), 2000-2004: 1 (8.33%), 2005-2009: 6 (21.42%), 2010-2015: 15 (42.85) expressing a statistical significant difference in compliance among the different time periods (p -value= 0.039)




Figure 2 Bar chart of >75% compliance of trials with the CONSORT checklist

DISCUSSION

This study show that reporting of RCTs in Multiple Sclerosis is still not optimal according to the CONSORT statement. Some of the reporting items are underreported. Some of them are not critical for the evaluation of the quality of the RCT like the item 3b (Important changes to methods after trial commencement, with reasons), 7b (explanation of any interim analyses and stopping guidelines) and 14b (why the trial ended or was stopped) which are mentioned only when applicable. Other items are important methodological techniques which should always be reported, like: item 8a (method used to generate the random allocation sequence) reported in 57% of the articles and item 9 (Mechanism to implement the random allocation sequence describing any steps taken to conceal the sequence until interventions were assigned) reported in 28% of the articles. Item 24 (where the full trial protocol can be accessed, if

Table 1. Proportion of reporting of 38 items in a total of 75 RCTs in MS by publication period

Data item	Combined 2000-2015 n=75 *	2000-2004 n=12	2005-2009 n=28	2010-2015 n=35
ABSTRACT / TITLE				
1a	0,77	0,92	0,61	0,86
1b	0,81	0,75	0,79	0,86
INTRODUCTION				
2a	1,00	1,00	1,00	1,00
2b	0,88	0,92	0,82	0,91
METHODS				
3a	0,87	0,67	0,89	0,91
3b	0,05	0,17	0,00	0,06
4a	0,89	0,92	0,79	0,97
4b	0,59	0,58	0,46	0,69
5	0,99	1,00	0,96	1,00
6a	0,96	1,00	0,93	0,97
6b	0,05	0,08	0,00	0,09
7a	0,65	0,58	0,54	0,77
7b	0,19	0,08	0,18	0,23
8a	0,57	0,42	0,54	0,66
8b	0,71	0,50	0,68	0,80
9	0,28	0,00	0,21	0,43
10	0,37	0,17	0,32	0,49
11a	0,64	0,42	0,61	0,74
11b	0,31	0,17	0,32	0,34
12a	0,96	0,92	0,93	1,00
12b	0,85	0,67	0,82	0,94
RESULTS				
13	0,85	0,75	0,79	0,94
13a	0,93	1,00	0,89	0,94
13b	0,88	0,83	0,86	0,91
14a	0,47	0,33	0,50	0,49
14b	0,09	0,17	0,04	0,11
15	0,97	1,00	0,96	0,97
16	0,91	0,83	0,89	0,94
17a	0,91	0,83	0,93	0,91
17b	0,73	0,50	0,75	0,80
18	0,76	0,75	0,68	0,83
19	0,83	0,58	0,75	0,97
DISCUSSION				
20	0,64	0,58	0,64	0,66
21	0,59	0,67	0,46	0,66
22	0,99	1,00	1,00	0,97
OTHER INFO				
23	0,53	0,00	0,32	0,89
24	0,03	0,00	0,00	0,06
25	0,87	0,83	0,79	0,94

* 1 Percentage of articles reporting the item

available) is the most underreported item, but it's a new entry in the CONSORT 2010 checklist. It is not reported in any article the two periods from 2000-2009 and in the 6% of the articles the period 2010-2015 showing a slow increase in compliance with the CONSORT.

Table 2 Numbers and percentages of items reported by 75% or more of the articles by reporting group

Checklist items / period	2000-2015 N(%)	2000-2004 N(%)	2005-2009 N(%)	2010-2015 N(%)
Overall (38)	20 (52.6)	17 (44.7)	19 (50)	24 (63.2)
Title/abstract – intro (4)	4 (100)	4 (100)	3 (75)	4 (100)
Methods (17)	6 (35.3)	4 (23.5)	6 (35.3)	8 (47.1)
Results (11)	8 (72.7)	7 (63.6)	8 (72.7)	9 (81.8)
Discussion (3)	1 (33.3)	1 (33.3)	1 (33.3)	1 (33.3)
Other info (3)	1 (33.3)	1 (33.3)	1 (33.3)	2 (66.7)

Although the quality of reporting is not optimal most of the items were reported in more articles at every time period indicating an improvement of reporting over time.

This study was not designed to evaluate the impact of the quality of the journal on the quality of reporting. It is our belief though that journals with greater Impact Factor are promoting a better and more “CONSORT-compliant” way of reporting.

In 2012 Signori et al. (21) in his review of the quality of reporting of RCTs (from 1993 to 2010) found some similar data. The identification of the trial as randomized in the title was 49.1% and we found it 77%. Similarly the allocation concealment method was reported as 17% (here 28%). The primary outcome definition founded similar to our results at 96.2% (here 96%). These data are enhancing the notion of improvement in reporting quality over time.

This study has its weaknesses. We used the revise CONSORT 2010 checklist for all the trials despite they were published before or after its publication. The search of trials and the review was made by only one person decreasing the validity of the procedure.

In conclusion, our attempt to assess the quality of RCTs, centering on Multiple Sclerosis, indicated an improvement of reporting of RCTs by time period. In the area of Multiple Sclerosis research, which is still searching for an effective treatment, further improving the quality of RCTs and their reporting could assist health care providers to their clinical decisions, increase the clinical significance of RCTs, and direct more specifically future medical research.

1. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. *Lancet* (London, England). 1993;341(8851):973-8.
2. Kober T, Trelle S, Engert A. Reporting of randomized controlled trials in Hodgkin lymphoma in biomedical journals. *Journal of the National Cancer Institute*. 2006;98(9):620-5.
3. Stolberg HO, Norman G, Trop I. Randomized controlled trials. *AJR American journal of roentgenology*. 2004;183(6):1539-44.
4. Pfeifer MP, Snodgrass GL. The continued use of retracted, invalid scientific literature. *Jama*. 1990;263(10):1420-3.
5. Olkin I. Meta-analysis: reconciling the results of independent studies. *Statistics in medicine*. 1995;14(5-7):457-72.
6. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet* (London, England). 1998;352(9128):609-13.
7. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *Jama*. 1995;273(5):408-12.
8. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *Jama*. 1996;276(8):637-9.
9. Mills EJ, Wu P, Gagnier J, Devereaux PJ. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. *Contemporary clinical trials*. 2005;26(4):480-7.
10. Huwiler-Muntener K, Juni P, Junker C, Egger M. Quality of reporting of randomized trials as a measure of methodologic quality. *Jama*. 2002;287(21):2801-4.
11. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ (Clinical research ed)*. 2001;323(7303):42-6.
12. Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized control trials of primary treatment of breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 1986;4(6):942-51.
13. Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. *The Cochrane database of systematic reviews*. 2012;11:Mr000030.
14. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMC medicine*. 2010;8:18.
15. Ziogas DC, Zintzaras E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. *Annals of epidemiology*. 2009;19(7):494-500.
16. Lai TY, Wong VW, Lam RF, Cheng AC, Lam DS, Leung GM. Quality of reporting of key methodological items of randomized controlled trials in clinical ophthalmic journals. *Ophthalmic epidemiology*. 2007;14(6):390-8.
17. Agha R, Cooper D, Muir G. The reporting quality of randomised controlled trials in surgery: a systematic review. *International journal of surgery (London, England)*. 2007;5(6):413-22.
18. Hill CL, Buchbinder R, Osborne R. Quality of reporting of randomized clinical trials in abstracts of the 2005 annual meeting of the American College of Rheumatology. *The Journal of rheumatology*. 2007;34(12):2476-80.
19. Farrokhyar F, Chu R, Whitlock R, Thabane L. A systematic review of the quality of publications reporting coronary artery bypass grafting trials. *Canadian journal of surgery Journal canadien de chirurgie*. 2007;50(4):266-77.
20. Mills E, Loke YK, Wu P, Montori VM, Perri D, Moher D, et al. Determining the reporting quality of RCTs in clinical pharmacology. *British journal of clinical pharmacology*. 2004;58(1):61-5.
21. Signori A, Baccino A, Sormani MP. The quality of reports of randomized trials in multiple sclerosis: a review. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2012;18(6):776-81.
22. Berer K, Krishnamoorthy G. Microbial view of central nervous system autoimmunity. *FEBS letters*. 2014;588(22):4207-13.

APPENDIX

CONSORT CHECKLIST (14)

Title and abstract

- 1a Identification as a randomised trial in the title
- 1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)

Introduction

Background and objectives

- 2a Scientific background and explanation of rationale
- 2b Specific objectives or hypotheses

Methods

Trial design

- 3a Description of trial design (such as parallel, factorial) including allocation ratio
- 3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons

Participants

- 4a Eligibility criteria for participants
- 4b Settings and locations where the data were collected

Interventions

- 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

Outcomes

- 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
- 6b Any changes to trial outcomes after the trial commenced, with reasons

Sample size

- 7a How sample size was determined
- 7b When applicable, explanation of any interim analyses and stopping guidelines

Randomisation:

Sequence generation

- 8a Method used to generate the random allocation sequence
- 8b Type of randomisation; details of any restriction (such as blocking and block size)

Allocation concealment mechanism

- 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Implementation

- 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Blinding

- 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
- 11b If relevant, description of the similarity of interventions

Statistical methods

- 12a Statistical methods used to compare groups for primary and secondary outcomes
- 12b Methods for additional analyses, such as subgroup analyses and adjusted analyses

Results

Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome
	13b	For each group, losses and exclusions after randomisation, together with reasons
Recruitment	14a	Dates defining the periods of recruitment and follow-up
	14b	Why the trial ended or was stopped
Baseline data	15	A table showing baseline demographic and clinical characteristics for each group
Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)

Discussion

Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
Generalisability	21	Generalisability (external validity, applicability) of the trial findings
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

Other information

Registration	23	Registration number and name of trial registry
Protocol	24	Where the full trial protocol can be accessed, if available
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders

LIST OF ARTICLES

1. Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. *Archives of neurology*. 2004;61(10):1515-20.
2. Andersen O, Elovaara I, Farkkila M, Hansen HJ, Mellgren SI, Myhr KM, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry*. 2004;75(5):706-10.
3. Arnold DL, Campagnolo D, Panitch H, Bar-Or A, Dunn J, Freedman MS, et al. Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. *Journal of neurology*. 2008;255(10):1473-8.
4. Bitarafan S, Harirchian MH, Sahraian MA, Keramatipour M, Beladi Moghadam N, Togha M, et al. Impact of vitamin A supplementation on RAR gene expression in multiple sclerosis patients. *Journal of molecular neuroscience : MN*. 2013;51(2):478-84.
5. Broadley SA, Vanags D, Williams B, Johnson B, Feeney D, Griffiths L, et al. Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2009;15(3):329-36.
6. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. *Neurology*. 2010;74(23):1852-9.
7. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. *The Lancet Neurology*. 2014;13(7):657-65.
8. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. *The Lancet Neurology*. 2014;13(6):545-56.
9. Chataway J, Schuerer N, Alsanousi A, Chan D, MacManus D, Hunter K, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. *Lancet (London, England)*. 2014;383(9936):2213-21.
10. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet (London, England)*. 2012;380(9856):1819-28.
11. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet (London, England)*. 2012;380(9856):1829-39.
12. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. *Lancet (London, England)*. 2001;357(9268):1576-82.
13. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. *Annals of neurology*. 2001;49(3):290-7.
14. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. *Lancet (London, England)*. 2009;374(9700):1503-11.
15. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet (London, England)*. 2008;371(9630):2085-92.

16. Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Neurology*. 2014;13(3):247-56.
17. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. *Acta neurologica Scandinavica*. 2006;113(5):283-7.
18. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. *Journal of neurology*. 2007;254(12):1723-8.
19. Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet (London, England)*. 2004;364(9444):1489-96.
20. Filippi M, Wolinsky JS, Comi G. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. *The Lancet Neurology*. 2006;5(3):213-20.
21. Friedman JE, Zabriskie JB, Plank C, Ablashi D, Whitman J, Shahan B, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2005;11(3):286-95.
22. Garren H, Robinson WH, Krasulova E, Havrdova E, Nadj C, Selmaj K, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. *Annals of neurology*. 2008;63(5):611-20.
23. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. *Lancet (London, England)*. 2013;381(9884):2167-75.
24. Gonsette RE, Sindic C, D'Hooghe M B, De Deyn PP, Medaer R, Michotte A, et al. Boosting endogenous neuroprotection in multiple sclerosis: the ASSociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2010;16(4):455-62.
25. Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. *Annals of neurology*. 2010;68(4):494-502.
26. Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. *Lancet (London, England)*. 2009;373(9665):732-8.
27. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. *Neurology*. 2009;72(9):806-12.
28. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. *Lancet (London, England)*. 2002;360(9350):2018-25.
29. Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2009;15(8):965-76.
30. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. *Annals of neurology*. 2009;66(4):460-71.
31. Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. *Lancet (London, England)*. 2004;364(9440):1149-56.
32. Kamm CP, El-Koussy M, Humpert S, Findling O, von Bredow F, Burren Y, et al. Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial. *Journal of neurology*. 2012;259(11):2401-13.
33. Kapoor R, Furby J, Hayton T, Smith KJ, Altmann DR, Brenner R, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. *The Lancet Neurology*. 2010;9(7):681-8.
34. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. *Lancet (London, England)*. 2008;372(9648):1463-72.

35. Kappos L, Hartung HP, Freedman MS, Boyko A, Radu EW, Mikol DD, et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. *The Lancet Neurology*. 2014;13(4):353-63.
36. Karussis D, Shor H, Yachnin J, Lanxner N, Amiel M, Baruch K, et al. T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial. *PloS one*. 2012;7(12):e50478.
37. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. *Annals of neurology*. 2013;73(6):705-13.
38. Khoury SJ, Healy BC, Kivisakk P, Viglietta V, Egorova S, Guttmann CR, et al. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. *Archives of neurology*. 2010;67(9):1055-61.
39. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. *The Lancet Neurology*. 2014;13(3):257-67.
40. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. *Neurology*. 2014;83(20):1780-8.
41. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. *Annals of neurology*. 2013;73(3):327-40.
42. Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, et al. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2009;15(10):1183-94.
43. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. *The Lancet Neurology*. 2008;7(10):903-14.
44. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Neurology*. 2014;13(10):977-86.
45. Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, et al. Finategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. *The Lancet Neurology*. 2012;11(2):131-9.
46. Montalban X, Sastre-Garriga J, Tintore M, Brieva L, Aymerich FX, Rio J, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2009;15(10):1195-205.
47. Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, et al. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. *Journal of neurology, neurosurgery, and psychiatry*. 2008;79(9):1027-31.
48. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. *The Lancet Neurology*. 2009;8(10):889-97.
49. Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. *Journal of neurology, neurosurgery, and psychiatry*. 2014;85(11):1198-208.
50. Pakdaman H, Sahraian MA, Fallah A, Pakdaman R, Ghareghozli K, Ghafarpour M, et al. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. *Acta neurologica Scandinavica*. 2007;115(6):429-31.
51. Pohlau D, Przuntek H, Sailer M, Bethke F, Koehler J, Konig N, et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2007;13(9):1107-17.
52. Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2003;9(4):342-8.
53. Ravnborg M, Sorensen PS, Andersson M, Celius EG, Jongen PJ, Elovaara I, et al. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. *The Lancet Neurology*. 2010;9(7):672-80.

54. Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, et al. Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. *Neurology*. 2014;82(1):41-8.
55. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. *Brain : a journal of neurology*. 2001;124(Pt 9):1803-12.
56. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2012;18(9):1269-77.
57. Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. *The Lancet Neurology*. 2008;7(9):796-804.
58. Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. *The Lancet Neurology*. 2013;12(8):756-67.
59. Skurkovich S, Boiko A, Beliaeva I, Buglak A, Alekseeva T, Smirnova N, et al. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2001;7(5):277-84.
60. Smith DR, Weinstock-Guttman B, Cohen JA, Wei X, Gutmann C, Bakshi R, et al. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2005;11(5):573-82.
61. Soilu-Hanninen M, Aivo J, Lindstrom BM, Elovaara I, Sumelahti ML, Farkkila M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry*. 2012;83(5):565-71.
62. Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, et al. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. *The Lancet Neurology*. 2009;8(6):519-29.
63. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2010;16(7):848-54.
64. Vermersch P, Czlonskowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2014;20(6):705-16.
65. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2004;10(1):89-91.
66. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2008;14(5):663-70.
67. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, et al. A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. *Journal of neurology*. 2014;261(4):773-83.
68. Vollmer TL, Wynn DR, Alam MS, Valdes J. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2011;17(2):181-91.
69. Wade DT, Young CA, Chaudhuri KR, Davidson DL. A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis. *Journal of neurology, neurosurgery, and psychiatry*. 2002;73(3):246-9.
70. Walker JE, Giri SN, Margolin SB. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2005;11(2):149-58.

71. Woessner R, Grauer MT, Frese A, Bethke F, Ginger T, Hans A, et al. Long-term antibiotic treatment with roxithromycin in patients with multiple sclerosis. *Infection*. 2006;34(6):342-4.
72. Wolf C, Sidhu J, Otoul C, Morris DL, Cnops J, Taubel J, et al. Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study. *PloS one*. 2013;8(3):e58438.
73. Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. *Annals of neurology*. 2007;61(1):14-24.
74. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. *The Lancet Neurology*. 2010;9(4):381-90.
75. Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. *The Lancet Neurology*. 2013;12(9):857-65.